remestemcel-L COVID-19

Weekend cell biology reads: Mesoblast COVID-19 deal, pubs

bergert cell stem cell 2020 cell mechanics sm

The COVID-19 pandemic is tearing through the country right as we are starting into the holiday season, but the wheels of science including cell biology keep going and we keep reading all the great work. What news or papers caught your eye? Here are some of the things I have on my list of reading. …

Weekend cell biology reads: Mesoblast COVID-19 deal, pubs Read More »

Mesoblast MSCs Quell Peds GvHD; On Road to FDA Approval?

MSCs-mesenchymal-stem-cells-stromal-cells-small

Graft-versus-host disease (GVHD) is counterintuitive In the weeks and months following a transplant, a major concern is the recipient’s immune system rejecting the “foreign” biological material. But in GVHD, the opposite happens: transplanted tissue unleashes a horde of T cells that spark a cascade of inflammation, within 100 days. Typically, GVHD follows a bone marrow …

Mesoblast MSCs Quell Peds GvHD; On Road to FDA Approval? Read More »

New Mesoblast “COVID kid” stem cell study

Dr-Fred-Grossman-CMO-Mesoblast.

The biotech Mesoblast is starting an expanded access study of its stem cell product for kids with a severe offshoot of COVID-19. The cellular drug in this case is remestemcel-L (more below). While most children fare better than adults in dealing with COVID-19, the rare subset of kids with COVID-19 for this study have more severe …

New Mesoblast “COVID kid” stem cell study Read More »

Cell therapy trials for COVID-19 accelerate & some early reports

MultiStem-Athersys-cell-therapy-COVID-19

Could various kinds of cell therapy help patients with COVID-19? A variety of cell therapies, mostly focused on mesenchymal stromal/stem cells (MSCs), have gotten cleared quickly in the U.S., China, and Israel and possibly other countries to be tested in patients with the novel coronavirus. I hope at least one proves helpful. It’s mostly a …

Cell therapy trials for COVID-19 accelerate & some early reports Read More »